NovoCure Limited (NVCR) News
Track canonical SquawkNews coverage tagged to NVCR, NovoCure Limited. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 10 indexed stories across 4 publication days and is ordered by the same first-publication timeline used by LiveCast.
M
Novocure reports unauthorized access to U.S. patient records
Novocure said unauthorized access exposed internal patient ID numbers and other contact data in more than 1,400 U.S. records, with no device access or operational impact.
REGULATION | Sep 01, 2026, 11:03 AM UTC
H
NovoCure's Strongest Quarter Ever Isn't Enough to Stop NVCR Stock From Sliding
NovoCure Ltd. (NASDAQ: NVCR ) shares rose in Friday’s premarket session before dropping after the company raised its full-year 2026 revenue outlook and reported second-quarter earnings and sales above analyst expectation
EARNINGS | Jul 24, 2026, 03:08 PM UTC
H
Crude Oil Rises Sharply; T-Mobile Shares Fall Following Q2 Results
U.S. stocks traded lower midway through trading, with the S&P 500 falling over 1% on Thursday. The Dow traded down 0.92% to 51,738.04 while the NASDAQ declined 2.03% to 25,169.19. The S&P 500 also fell, dropping, 1.16% t
CENTRAL_BANK | Jul 23, 2026, 05:31 PM UTC
H
Lockheed Martin, Quest Diagnostics, Thermo Fisher Scientific And Other Big Stocks Moving Higher On Thursday
U.S. stocks were lower, with the Dow Jones index dipping around 450 points on Thursday. Shares of Lockheed Martin Corp (NYSE: LMT ) rose sharply after the company reported better-than-expected second-quarter financial re
EARNINGS | Jul 23, 2026, 02:20 PM UTC
H
Transcript: NovoCure Q2 2026 Earnings Conference Call
NovoCure (NASDAQ: NVCR ) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. This transcript is brought to you APIs. For real-time access to our entire c
EARNINGS | Jul 23, 2026, 01:07 PM UTC
L
NVCR Novocure RESULTS: Q2, Q2 Operating Income $-10.562M, Q2 pretax profit $-12.452M, Q2 REV $183.584M vs. EST $172.4M, Q2 gross profit $142
NVCR Novocure RESULTS: Q2, Q2 Operating Income $-10.562M, Q2 pretax profit $-12.452M, Q2 REV $183.584M vs. EST $172.4M, Q2 gross profit $142.478M, Q2 Net Income $-15.658M
EARNINGS | Jul 23, 2026, 11:14 AM UTC
L
Novocure raises FY26 revenue view to $710M-$725M from $690M-$710M
Raises FY26 adjusted...
EQUITY | Jul 23, 2026, 11:07 AM UTC
L
Novocure reports Q2 EPS (13c), consensus (33c)
Reports Q2 revenue...
EQUITY | Jul 23, 2026, 11:06 AM UTC
H
NovoCure Raises FY2026 Sales Guidance from $690.000M-$710.000M to $710.000M-$725.000M vs $708.743M Est
NovoCure (NASDAQ: NVCR ) raises FY2026 sales outlook from $690.000 million-$710.000 million to $710.000 million-$725.000 million vs $708.743 million estimate.
EARNINGS | Jul 23, 2026, 11:01 AM UTC
L
serial disappointer risk (missed last qtr) in EPS reporters tonight and tomorrow morning - GOOGL, CCI, GGG, SON, EPRT, CVBF, CASH, OSBC, OBK
serial disappointer risk (missed last qtr) in EPS reporters tonight and tomorrow morning - GOOGL, CCI, GGG, SON, EPRT, CVBF, CASH, OSBC, OBK, CBAN, BDN, CYH, ACU, LMT, HBAN, LUV, SNA, CLF, LAZ, VC, NVCR, DCOM, AMAL
EARNINGS | Jul 22, 2026, 07:07 PM UTC